- This is the sixth BTD granted for venetoclax as AbbVie continues to show ongoing commitment across blood cancers including tough to treat myeloid malignancies
PR Newswire
NORTH CHICAGO, Ill., July 21, 2021
PR Newswire
NORTH CHICAGO, Ill., July 21, 2021
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey